Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Are the Projected Market Size and Growth Rates for the B-Cell Maturation Antigen (BCMA) Targeted Therapies Market From 2025 To 2029?
The market size for therapies targeting b-cell maturation antigen (bcma) has seen significant expansion in recent years. It’s projected to rise from $12.17 billion in 2024 to $15.09 billion in 2025, with a compound annual growth rate (CAGR) of 24.0%. This growth during the historical period can be attributed to various factors such as increasing attention towards hematologic malignancies, escalating investments in oncology research, a burgeoning demand for personalized treatments, a growing preference for CAR-T cell therapies, and an increase in healthcare spending.
The market size for b-cell maturation antigen (bcma) targeted therapies is forecast to experience a surge in the subsequent years, growing to$35.81 billion in 2029 with a compound annual growth rate (CAGR) of 24.1%. The driving forces behind the predicted growth in the forecast period are due to an increased focus on cancer research, a shift towards specific molecular markers, a rising incidence of cancers, a surge in biotech investments, and a climbing utilization of cell and gene therapies. In the forecast period, the main market trends are anticipated to be innovations like CRISPR technology, progress in gene-editing technologies, advancements in next-generation car-t cell therapies, improved targeted antibody-drug conjugates, and the evolution of ready-made treatments.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20718&type=smp
Which Major Market Drivers Are Expected to Boost the Growth Potential of the B-Cell Maturation Antigen (BCMA) Targeted Therapies Market?
The upward trajectory of multiple myeloma incidents is anticipated to stimulate the development of the market for b-cell maturation antigen (BCMA) targeted therapies. Multiple myeloma, a type of cancer that predominantly impacts plasma cells – vital elements of the immune system for antibody production – has seen an increase in its incidence. Factors such as an aging global populace, advancements in diagnostic procedures, and healthcare accessibility variances contribute to this increment. BCMA targeted therapies mark a significant milestone in multiple myeloma treatment by focussing on malignant plasma cells expressing BCMA, paving the way for more efficient and specific treatment. For instance, in 2024, the American Cancer Society reported an estimated 35,780 new instances of multiple myeloma in the United States, including 19,520 in men and 16,260 in women. Furthermore, a projected 12,540 deaths were recorded, consisting of 7,020 males and 5,520 females. Hence, the escalating incidence of multiple myeloma is a significant driver for the growth of the BCMA targeted therapies market.
Which Key Market Segments Comprise the B-Cell Maturation Antigen (BCMA) Targeted Therapies Market and Drive Its Revenue Growth?
The b-cell maturation antigen (bcma) targeted therapiesmarket covered in this report is segmented –
1) By Product Type: Antibody Drug Conjugates; Chimeric Antigen Receptor T (CAR-T)-Cell Therapy; Bispecific Antibodies
2) By Indication Type: Acute Lymphoblastic Leukemia; Multiple Myeloma
3) By End User: Hospitals; Specialty Clinics; Home Care Settings
Subsegments:
1) By Antibody Drug Conjugates: BCMA-Targeted ADCs (Antibody-Drug Conjugates); Linker-Payload Technology-Based BCMA ADCs
2) By Chimeric Antigen Receptor T (CAR-T)-Cell Therapy: BCMA CAR-T Cells (Autologous); Allogeneic BCMA CAR-T Cells
3) By Bispecific Antibodies: BCMA x CD3 Bispecific Antibodies; BCMA x CD28 Bispecific Antibodies
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=20718&type=smp
Which Areas Are Leading Regions in the B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Expansion Across the Globe?
North America was the largest region in the B-cell maturation antigen (BCMA) targeted therapies market in 2024. The regions covered in the B-cell maturation antigen (BCMA) targeted therapies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Are the Key Market Trends in theB-Cell Maturation Antigen (BCMA) Targeted Therapies Market Over the Coming Years?
Prominent firms functioning in the B-cell maturation antigen (BCMA) targeted therapies industry are directing their efforts toward the development of groundbreaking treatments such as CAR-T cell therapy to heighten the accuracy and effectiveness of cancer cell targeting. This type of immunotherapy adjusts the patient’s T cells to convey chimeric antigen receptors (CARs) specifically intended to identify and eradicate cancer cells. For instance, Johnson & Johnson, a pharmaceutical titan based in the US, was granted approval by the U.S. Food and Drug Administration (FDA) for its CARVYKTI in April 2024. CARVYKTI (ciltacabtagene autoleucel) is a BCMA-oriented, genetically altered autologous T-cell immunotherapy prescribed for adult patients suffering from relapse or unresponsive multiple myeloma that have undergone at least one previous line of therapy and are resistant to lenalidomide.
View the full report here:
How Is the B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Conceptually Defined?
B-cell maturation antigen (BCMA) targeted therapies refer to a class of treatments designed to specifically target BCMA, a protein expressed on the surface of mature B-cells and plasma cells. BCMA is a member of the tumor necrosis factor (TNF) receptor superfamily and plays a key role in B-cell development, survival, and differentiation into plasma cells. BCMA-targeted therapies represent a significant advancement in the treatment of multiple myeloma, offering effective options for patients with relapsed or refractory disease.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20718
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
